Loading
Everything OnCo dates to 2026: 471 entries, 113 papers, 79 trials reported, 77 regulatory events and 68 landmarks. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
471 dated entries in OnCo fall in 2026: 113 papers, 79 trials reported, 77 regulatory events, 68 landmarks, 56 approvals, 27 financing rounds, 24 expected dates, 24 papers listed on people's pages, 1 company founded, 1 technology and 1 guideline change.
Of those, 68 to the day, 14 to the month, 17 to the quarter and 372 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Fixed-duration acalabrutinib + venetoclax, previously untreated CLL/SLL without del(17p)/TP53 (AMPLIFY)
Adults with haematological malignancies undergoing matched-donor haematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologi...
Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with lazertinib.
Untreated advanced non-small-cell lung cancer with an activating EGFR exon 20 insertion, with carboplatin and pemetrexed.
Risk stratification in early-stage HR+/HER2- invasive breast cancer
Adjuvant muscle-invasive bladder cancer, ctDNA-positive after cystectomy
Aumseqa: first-line advanced NSCLC with EGFR exon 19 deletion or L858R; advanced EGFR T790M-positive NSCLC
Adjuvant clear-cell RCC with pembrolizumab
First- and second-line metastatic colorectal cancer with fluoropyrimidine-based chemotherapy, only when targeted treatment or immunotherapy is unsuitable.
ER+/HER2- advanced breast cancer with emergent ESR1 mutation, with a CDK4/6 inhibitor; 20 Jul 2026
HR+/HER2- advanced breast cancer with an emergent ESR1 mutation on AI + CDK4/6, with a CDK4/6 inhibitor (accelerated, 4 Sep 2026)
PTEN-deficient metastatic prostate cancer with abiraterone
Untreated locally advanced non-small-cell lung cancer unsuitable for definitive chemoradiation, or metastatic disease, with PD-L1 in 1 percent or more of tumour cells and no EGFR o...
With teclistamab after ≥1 line (MajesTEC-3); high-risk smouldering myeloma (AQUILA)
Metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or in adults who are not candidates for multiagent systemic therapy.
First-line unresectable/metastatic TNBC, PD-1/PD-L1 inhibitor ineligible
Newly diagnosed AML, unfit for intensive induction, with venetoclax (ASCERTAIN-V)
High-risk NMIBC with BCG
First-line BRAF V600E mCRC with cetuximab and chemotherapy
Metastatic colorectal cancer with a BRAF V600E mutation. Traditional approval granted 24 February 2026, converting the accelerated approval.
HR+/HER2- advanced breast cancer after CDK4/6 inhibitor (July 2026)
Multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, with subcutaneous daratumumab and dexamethasone (Zenbexus, label effe...
ESR1-mutant ER+/HER2- mBC; 9 Jan 2026
Subcutaneous formulation (Sarclisa Escena)
Untreated advanced EGFR mutation-positive non-small-cell lung cancer (exon 19 deletion or L858R), with amivantamab.
Maintenance with atezolizumab in ES-SCLC after first-line induction; 29 May 2026
Label expansion (July 2026)
BCG-unresponsive NMIBC with CIS; 28 May 2026 (conditional). Conditional marketing authorisation
Resectable non-small-cell lung cancer at high risk of recurrence without an EGFR mutation or ALK rearrangement: neoadjuvant with platinum chemotherapy then adjuvant alone.
Untreated advanced classical Hodgkin lymphoma with AVD, age ≥12
BCG-unresponsive NMIBC with CIS, with BCG; 16 Feb 2026 (conditional). Conditional marketing authorisation
Locally advanced pancreatic cancer with chemotherapy
Unresectable stage III EGFR mutation-positive non-small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy.
HR+/HER2+ advanced breast cancer maintenance with anti-HER2 and endocrine therapy
Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC
Pylarify TruVu formulation
Blastic plasmacytoid dendritic cell neoplasm
Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel
Erythrocytosis in adults with polycythaemia vera
First-line unresectable locally advanced or metastatic TNBC in patients who are not candidates for PD-1 or PD-L1 inhibitor therapy (ASCENT-03); listed in the EMA therapeutic indica...
First-line metastatic TNBC: monotherapy (PD-1 ineligible) or with pembrolizumab (PD-L1 CPS ≥10)
Label update (July 2026)
Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide. TA1167, published 18 June 2026 (ASTRUM-005); must be funded in England within 90 days of publicati...
Acquired hypothalamic obesity in adults and children aged 4 years and older. Approved 19 March 2026 (Drugs@FDA supplement 9) on the TRANSCEND trial
Colorectal cancer screening in average-risk adults aged 45 and older
Relapsed/refractory mantle cell lymphoma after ≥2 lines including a BTK inhibitor (accelerated)
ES-SCLC after platinum-based chemotherapy; 29 May 2026
Relapsed/refractory myeloma after ≥1 prior therapy
Relapsed/refractory paediatric low-grade glioma (conditional)
Early-stage HER2+ breast cancer (neoadjuvant and post-neoadjuvant)
ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after endocrine therapy
Unresectable/metastatic melanoma after anti-PD-1, with nivolumab (accelerated)
HER2-positive (IHC 3+) unresectable locally advanced or metastatic biliary tract cancer after at least one line of systemic treatment; MHRA 19 February 2026, NICE TA1153 published...
NRG1-fusion cholangiocarcinoma
ROS1+ NSCLC (July 2026)
First-line HER2-mutant non-squamous NSCLC
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Rolling BLA initiated; completion expected Q4 2026
First-line metastatic phase 3 missed its primary PFS endpoint (Regeneron release)
BLA submitted by Summit for EGFR-mutant NSCLC after TKI (HARMONi)
EPCORE DLBCL-1 topline: PFS met, OS (US primary endpoint) not met
Final PMA module submitted
Resubmission accepted; PDUFA 23 July 2026
BLA accepted; PDUFA 27 December 2026
Positive topline phase 2 FOURLIGHT-1
Acalabrutinib + venetoclax fixed duration (AMPLIFY)
NDA accepted (evERA, ESR1-mutant)
Positive interim phase 3 in pretreated TNBC (BL-B01D1-307) announced; regulatory submissions follow
First-line advanced classical Hodgkin lymphoma with AVD, age ≥12 (SWOG S1826)
sBLA for frontline high-risk DLBCL (frontMIND) planned H1 2026
Withdrawn over secondary haematologic malignancies
Programme deprioritised after regulatory feedback on Duravelo-2 design
Teclistamab + daratumumab after ≥1 prior line
persevERA primary endpoint not met
Pylarify TruVu formulation
ODAC voted 6-3 against (clinical relevance of ctDNA-triggered switch)
FDA clearance: first digital-pathology-based risk stratification tool for early HR+/HER2- breast cancer
With venetoclax in newly diagnosed unfit AML
Accelerated approval in MCL; priority review, Project Orbis
First-line unresectable/metastatic TNBC, PD-1/PD-L1 inhibitor ineligible (TROPION-Breast02)
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy
High-risk non-muscle-invasive bladder cancer with BCG (POTOMAC)
Adjuvant clear-cell RCC with pembrolizumab (LITESPARK-022)
PTEN-deficient metastatic prostate cancer with abiraterone (CAPItello-281)
Adjuvant RCC with belzutifan (LITESPARK-022)
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Maintenance in HR+/HER2+ advanced breast cancer with anti-HER2 and endocrine therapy (PATINA)
First-line PD-L1+ TNBC with sacituzumab govitecan (ASCENT-04)
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
First-line metastatic TNBC: monotherapy (PD-1 ineligible, ASCENT-03) and with pembrolizumab (CPS ≥10, ASCENT-04)
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
CHMP negative opinion on Tacquell (autologous TIL) for melanoma; applicant Netherlands Cancer Institute
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq (Tregzi, Orca Bio) on the Precision-T trial
Subcutaneous on-body injector
Commissioner's National Priority Voucher (CNPV) awarded
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications
Muscle-invasive bladder cancer with pembrolizumab, with or without berahyaluronidase alfa
Muscle-invasive bladder cancer with enfortumab vedotin, as pembrolizumab or pembrolizumab with berahyaluronidase alfa
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
HR+/HER2- advanced breast cancer after CDK4/6 inhibitor with palbociclib and fulvestrant (VIKTORIA-1)
Gedatolisib with fulvestrant, with or without palbociclib, HR+/HER2- advanced breast cancer (VIKTORIA-1)
Traditional approval, locally advanced or metastatic RET fusion-positive solid tumours
NDA 220910 received by the FDA on the RASolute 302 result
ROS1+ NSCLC after at least one prior ROS1 TKI (ARROS-1)
Third CRL, again cGMP
XPORT-EC-042 misses primary endpoint; endometrial development deprioritised
PSMA+ metastatic hormone-sensitive prostate cancer with ARPI (PSMAddition)
Accelerated approval of vusolimogene oderparepvec in combination with nivolumab, unresectable advanced cutaneous melanoma
Accelerated approval with nivolumab for unresectable/metastatic melanoma after anti-PD-1 (IGNYTE)
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
Phase 3 INTerpath-001 met RFS and DMFS endpoints; filings to follow
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma
First-line HER2-positive gastric, gastro-oesophageal junction or oesophageal adenocarcinoma with tislelizumab and fluoropyrimidine-platinum chemotherapy
NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent sys...
PDUFA goal date for GEP-NET indication
Accelerated approval (Etcamah)
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer
FDA Molecular and Clinical Genetics Panel meeting
PDUFA target date
Full approval in first-line BRAF V600E mCRC with OS benefit
Optune Pax, locally advanced pancreatic cancer with chemotherapy (PANOVA-3)
Platinum-resistant PD-L1+ ovarian cancer
Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel
Relapsed/refractory myeloma after ≥1 prior line, with daratumumab (MajesTEC-3)
First-line HER2-mutant non-squamous NSCLC
Label extended to patients aged 12 and older
Adjuvant ctDNA-positive muscle-invasive bladder cancer (IMvigor011): first ctDNA-guided indication
Used to select ctDNA-positive patients in the first ctDNA-guided drug approval (IMvigor011, atezolizumab)
Early-stage HER2+ breast cancer: neoadjuvant (DESTINY-Breast11) and post-neoadjuvant residual disease (DESTINY-Breast05)
Displaced post-neoadjuvantly by T-DXd approval (DESTINY-Breast05)
ESR1-mutated ER+/HER2- advanced breast cancer after endocrine therapy: first PROTAC approved
NRG1-fusion cholangiocarcinoma
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
1 row recategorised. Anchored to Approval of trastuzumab deruxtecan for residual disease after neoadjuvant therapy, 2026 (DESTINY-Breast05).
The year reported on trial records, with the headline result the record gives.
Objective response 64 percent after platinum chemotherapy and 85 percent in previously untreated RET fusion-positive non-small-cell lung cancer; intracranial response 91 percent.
Median disease-free survival 9.30 against 5.55 months (hazard ratio 0.79, p=0.107): primary endpoint not met.
Primary DFS endpoint not met.
CR 41.6%; median time to CR 2 months.
Primary endpoint (sustained cCR at 12 months) met; rates pending congress presentation.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).
Co-primary endpoints including OS met (July 2026); numbers pending.
At the final analysis (median follow-up 38.5 months) overall survival favoured perioperative tislelizumab (hazard ratio 0.65, 95 percent confidence interval 0.45 to 0.93, p=0.009)...
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not ye...
Stopped early; primary endpoint not met.
PFS HR ~0.70 (interim); OS immature.
PFS HR 0.74; OS HR 0.96 (NS).
Primary PFS endpoint not met; numerical +5.1 months median PFS at the high dose.
PFS improved (HR not yet published in detail).
EFS HR 0.80 (0.62 to 1.03), p 0.083, not significant; OS HR 0.86 (0.62 to 1.19).
Interim PFS not statistically significant (May 2026); final readouts pending.
PFS 12.4 vs 8.1 months (HR 0.63-0.65); OS significantly improved.
RFS and DMFS significantly improved (HRs pending presentation).
Superior PFS and OS vs approved G12C inhibitors (topline, July 2026).
Final progression-free survival 14.8 vs 10.7 months (hazard ratio 0.70, 95% CI 0.59 to 0.84; one-sided p<0.0001).
Primary endpoint not met (ASCO GU 2026).
DFS significantly improved vs pembrolizumab (interim; HR presented ASCO GU 2026).
Three-year progression-free survival 78 percent after high-dose chemotherapy and autologous transplant against 51 percent after non-myeloablative R-DeVIC (hazard ratio 0.43, p 0.00...
Median OS 10 vs 5 months, HR 0.54.
OS and PFS significantly improved at interim analysis; numbers per ASCO 2026 presentation.
Median overall survival 38.2 months with enzalutamide plus radium-223 against 32.6 months with enzalutamide alone (hazard ratio 0.76, 95 percent confidence interval 0.60 to 0.96, p...
PFS 33.1 vs 28.2 months, not significant.
OS 13.2 vs 6.7 months, HR 0.40.
Second-line daraxonrasib 300 mg in 26 patients with RAS G12-mutated pancreatic cancer: objective response 35 percent, median progression-free survival 8.5 months, median overall su...
Least-squares mean change in body-mass index at 52 weeks minus 16.5% with setmelanotide vs plus 3.3% with placebo (P<0.001); hunger score change minus 2.73 vs minus 1.45 (P = 0.009...
Primary PFS endpoint not met; mPFS 12.75 vs 7.43 months (mITT) not significant.
The publication year on key paper records.
Tagawa ST, Sartor O, Piulats JM, et al. The Lancet.
Mahadevan D, Parekh J, Beck JT, et al. Investigational new drugs.
Yeh CM, Yu CC, Lee AF, et al. Clinical Cancer Research.
Robert M, Kotecki N, Gomez-Roca C, et al. European Journal of Cancer.
Zhou H, Zhou Q, Guo Q, et al. Lung cancer.
Wu YL, Majem M, John T, et al. Journal of Thoracic Oncology.
DeWeese TL, Manzanera A, Sylvester J, et al. The Lancet Oncology.
Oberstein PE, Hecht JR, Raghav K, et al. Journal of Clinical Oncology.
Carlino MS, Kapiteijn E, Piperno-Neumann S, et al. Nature Medicine.
Yang JJ, Mu Y, Wang ZH, et al. Journal of Thoracic Oncology.
Armstrong AJ, Petrylak DP, Shore ND, et al. European Urology.
Sinicrope FA, Ou FS, Arnold D, et al. New England Journal of Medicine.
Zhang L, Zhang X, Wu L, et al. The Lancet Oncology.
Li Z, Hu J, Chen J, et al. The Lancet Oncology.
Motzer RJ, McDermott R, Park SH, et al. The Lancet.
Gradishar WJ, Moran MS, Abraham J, et al. Journal of the National Comprehensive Cancer Network.
Cunningham N, Cutts RJ, Swift C, et al. JAMA Oncology.
Guilford FT, Yu S. Integrative Medicine (Encinitas).
Fizazi K, Clarke NW, De Santis M, et al. Annals of Oncology.
Schmid P, McArthur HL, Cortés J, et al. Annals of Oncology.
Tamrakar VK, Sharma K, Singh P, et al. Cancer.
Bar V, Zundelevich A, Gavert N, et al. Journal of personalized medicine.
Wolpin BM, Park W, Garrido-Laguna I, et al. New England Journal of Medicine.
O'Reilly EM, Wainberg ZA, Hendifar AE, et al. New England Journal of Medicine.
Zacharia GS, Pandey U, Thartori O, et al. Cureus.
Saad F, Shore N, Vjaters E, et al. European Urology.
Schmid P, Wang HC, Lynce F, et al. Annals of Oncology.
Dent R, Shao Z, Schmid P, et al. Annals of Oncology.
Huang J, Chen G, Wang Z, et al. Journal of Thoracic Oncology.
Wu J, Li X, Gu C, et al. Signal transduction and targeted therapy.
Suter RK, Jermakowicz AM, Veeramachaneni R, et al. Nature Communications.
Powderly GE, Hassevoort K, Loy M, Balonier J, Sievers C. Cureus.
Li JJ, Zhang WJ, Zeng XH, et al. Journal of Clinical Oncology.
Tang W, Lv Y, Xie H, et al. Cancer letters.
Oh DY, Lugowska I, Stroyakovskiy D, et al. ESMO Open.
Mahalingam D, Shroff RT, Carneiro BA, et al. Nature Medicine.
Wen PY, Berry DA, Buxton MB, et al. Journal of Clinical Oncology.
Boissiere-Michot F, Gudin-De-Vallerin A, Thezenas S, et al. Virchows Archiv.
Xin X, Miao R. Cancers.
Liu Y, Zhang Y, Lin R, et al. Signal transduction and targeted therapy.
Shao X, Tian C, Chen Z, et al. Nature Medicine.
Reck M, Patel JD, Gray JE, et al. Journal of Thoracic Oncology.
Zhou C, Greillier L, Liu G, et al. New England Journal of Medicine.
Wakelee H, Spicer JD, Gao S, et al. Annals of Oncology.
Planchard D, Jänne PA, Yang JC, et al. Lung Cancer.
Gárate-Calderón V, Kumar R, Marcelain K, et al. EBioMedicine.
Zhong J, Zhao J, Duan J, et al. The Lancet. Respiratory medicine.
Cho BC, Balaraman R, Chen HJ, et al. Nature Medicine.
Angerilli V, Gasparello J, Niero M, et al. Human Pathology.
Dieras V, Curigliano G, Martin M, et al. Journal of Clinical Oncology.
Braun DA, Noel MS, Moy RH, et al. Cell reports. Medicine.
Conroy S, Keane E, Rehman B, et al. The Breast Journal.
Kapoor A, Gupta A, Sansar B, et al. JCO global oncology.
Khattak A, Carlino MS, Meniawy T, et al. Journal of Clinical Oncology.
Yilmaz S, Göktaş B, Ateş İ, Çelik M. Journal of Applied Toxicology.
Rockwell MS, Kahn KL, Fendrick AM, Vangala S, Mafi JN. JAMA Network Open.
Le X, Passaro A, Zhao Y, et al. The Lancet Oncology.
Lu S, Liu B, Luo Y, et al. The Lancet.
Barlesi F, Yao W, Duruisseaux M, et al. Future Oncology.
Ballman KV. Journal of Clinical Oncology.
Saperstein Y, Bou Sanayeh E, Boazak P, Itani H, Moussa E, Gut T. Postgraduate Medicine.
Kaminski MF, Kalager M, Løberg M, et al. The Lancet.
Li W, Zhang Y, Fan H, et al. Journal of Clinical Oncology.
Sushentsev N, Warren AY, Colling R, et al. BJU international.
McClements J, Lee WT, Koh A, et al. British Journal of Surgery.
Illerhaus G, Ferreri AJM, Wendler J, et al. The Lancet.
Cheng R, Araujo DV. Frontiers in Oncology.
Cowzer D, Walch H, Atri P, et al. Clinical Cancer Research.
Morris VK, Ciombor KK, Xiao L, et al. Journal of Clinical Oncology.
Li J, Liu T, Yu KD, et al. JAMA Oncology.
Hauschild A, Hassel JC, Ziemer M, et al. Journal of Clinical Oncology.
Harbeck N, Modi S, Pusztai L, et al. Annals of Oncology.
Akgör U, Temiz BE, Cengiz M, et al. Vaccines.
Johnston S, Martin M, O'Shaughnessy J, et al. Annals of Oncology.
Metzger O, Mandrekar S, Goel S, et al. New England Journal of Medicine.
Murciano-Goroff YR, Hollebecque A, Heist RS, et al. Nature Communications.
Worthington C, Raitses-Gurevich M, Innamorati G, et al. International Journal of Cancer.
Agarwal N, Matsubara N, Azad AA, et al. New England Journal of Medicine.
Casarini IA, Kowalski DM, Caglevic C, et al. JCO Oncology Practice.
Neal RD, Dolly S, Johnson P, et al. Nature Medicine.
Taplin ME, Gleave M, Shore ND, et al. New England Journal of Medicine.
Wang C, Wang W, Liu H, et al. Annals of Oncology.
Dumbrava EE, Shapiro GI, Parikh AR, et al. New England Journal of Medicine.
Lee JB, Baek S, Kim DK, et al. Journal for ImmunoTherapy of Cancer.
Pugh J, Wilkinson D, Savulescu J. Journal of Medical Ethics.
Malla M, Esmail A, Tin A, et al. ESMO Gastrointestinal Oncology.
Hulscher N, Victory K, Thorp JA, et al. Anticancer Research.
Ma H, Li Z, Shu P, et al. Pathology, research and practice.
Esserman LJ, Fiscalini AS, Naeim A, et al. JAMA.
Tolaney SM, de Azambuja E, Kalinsky K, et al. New England Journal of Medicine.
Fang W, Wu L, Meng X, et al. New England Journal of Medicine.
Xiong A, Yao W, Zheng W, et al. The Lancet.
Tutt A, Nowecki Z, Szoszkiewicz R, et al. Clinical Cancer Research.
Wu YL, Hochmair M, Yang Y, et al. New England Journal of Medicine.
Miller JL, van Santen HM, Phillips SA, et al. New England Journal of Medicine.
Peters S, Herbst R, Horinouchi H, et al. Journal of Clinical Oncology.
Lu S, Fang J, Yu Y, et al. Journal of Thoracic Oncology.
McClements J, Lee WT, Lucocq J, et al. HPB.
Garber JE, Cameron D, Campbell C, et al. Annals of Oncology.
Wu F, Zhang W, Zhao Y, et al. Journal of Thoracic Oncology.
Zhao Y, Liu H, Meng X, et al. New England Journal of Medicine.
Girard N, Goldman J, Lu S, et al. JTO clinical and research reports.
Hudson-Phillips SP, Nanda A, Attia M, et al. Clinical Breast Cancer.
Browne IM, Pascual J, Cutts RJ, et al. Clinical Cancer Research.
Selvakumar B, Patkar S, Nekarakanti PK, et al. HPB.
Zhang J, Ouyang Q, Zhang Q, et al. Journal of Clinical Oncology.
Liu Y, Li D, Wu L, et al. Clinical lung cancer.
Loibl S, Park YH, Shao Z, et al. New England Journal of Medicine.
Tolaney SM, Jiang Z, Zhang Q, et al. New England Journal of Medicine.
Yao H, Zhang Q, Li H, et al. The Lancet Oncology.
Wang S, Zhang Q, Jiang Z, et al. ESMO Open.
Hurvitz SA, Loi S, O'Shaughnessy J, et al. Annals of Oncology.
Strickler JH, Cercek A, Siena S, et al. Nature Communications.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Pancreatic ductal adenocarcinoma. FUT3-null patients, about 10%, have median CA 19-9 of 2.4 U/mL and the same poor survival as patients above 200; a value of 7 or below identifies...
Chronic lymphocytic leukaemia
Neuroblastoma (paediatric)
Glioma & glioblastoma
Rectal cancer
Triple-negative breast cancer (TNBC). Iza-bren phase 3 positive (Feb 2026); FDA approves Dato-DXd and sacituzumab govitecan first line (Q2 2026).
Colorectal cancer
Gallbladder cancer. 285 incidental cancers and 516 operated patients across 24 centres, 2014 to 2022; 67.7 percent of incidental cancers had liver resection.
Metastatic hormone-sensitive prostate cancer
Extrapulmonary neuroendocrine carcinoma
Mesothelioma
Hepatocellular carcinoma
Intermediate hepatocellular carcinoma (BCLC B)
Neuroendocrine tumours
Acute myeloid leukaemia. Decitabine-cedazuridine + venetoclax approved 13 May 2026 (ASCERTAIN-V, CR 41.6%).
HR-positive / HER2-negative breast cancer
Chronic lymphocytic leukaemia. Acalabrutinib-venetoclax approved 19 February; sonrotoclax accelerated approval 13 May; CaDAnCe-304 and CELESTIAL-TNCLL enrolling.
Metastatic triple-negative breast cancer
Lung cancer (all types). Over two million people invited and 7,193 lung cancers diagnosed to March 2025, 63.1 percent at stage 1 and 12.6 percent at stage 2, with the early-stage s...
Diffuse large B-cell lymphoma
BRAF V600E-mutant colorectal cancer
Triple-negative breast cancer (TNBC). Boissiere-Michot reclassifies 367 untreated TNBCs as 38% null, 38% ultralow and 24% low, none prognostic; ultralow stays unlabelled in TNBC.
Gastric & gastro-oesophageal junction cancer
Bladder & urothelial cancer
Bladder & urothelial cancer
Colorectal cancer. The American Cancer Society reports colorectal cancer incidence rising 3 percent a year in adults aged 20 to 49 and 0.4 percent a year at 50 to 64, while falling...
Stage IIB and IIC melanoma
Stage III melanoma (after surgery)
Melanoma
Melanoma
Oesophageal cancer
Renal cell carcinoma
Buccal mucosa and gingivobuccal cancer (oral cancer in India)
Hodgkin lymphoma
Hodgkin lymphoma
Oesophageal cancer
Small-cell lung cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN). CD123 ADC (CADENZA), FDA May 2026.
Prostate cancer
Metastatic pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma. ASCO plenary and NEJM; FDA approval of daraxonrasib on 26 August 2026; Optune Pax approved; zoldonrasib combinations reported; AMPLIFY-7P vaccine...
KRAS G12C-mutant pancreatic ductal adenocarcinoma
Platinum-resistant ovarian cancer
Ovarian cancer
Ovarian cancer. First immunotherapy approval in ovarian cancer (February 2026).
Advanced melanoma (unresectable stage III and stage IV)
Polycythaemia vera (PV). FDA approval for phlebotomy-dependent polycythaemia vera.
Myeloproliferative neoplasms (PV, ET, myelofibrosis). VERIFY: hepcidin mimetic controls erythrocytosis without phlebotomy; FDA approval August 2026.
Endometrial cancer. Post-hoc TP53-wild-type subgroup hypothesis not confirmed.
Thyroid cancer
Mantle cell lymphoma
Acute lymphoblastic leukaemia. Subcutaneous blinatumomab trials (including the first in mixed-phenotype leukaemia) aim to replace continuous infusion; infant trials integrate blina...
HER2-positive breast cancer
Follicular lymphoma. Secondary haematologic malignancies; EZH2 leaves the FL armamentarium.
Epithelioid sarcoma. Ipsen withdraws tazemetostat in all indications on 9 March 2026 after the SYMPHONY-1 data monitoring committee flagged secondary haematologic malignancies (18/...
Sarcomas (soft tissue, bone, GIST)
Multiple myeloma
Multiple myeloma
Breast cancer (all types). Published 3 July 2025 and recommended from 1 January 2026. For breast the classification is unchanged; the yp classification is clarified, basing ypT on...
Triple-negative breast cancer (TNBC). Datopotamab deruxtecan first line: overall survival 23.7 vs 18.7 months.
Locally advanced unresectable pancreatic ductal adenocarcinoma
HR-positive metastatic breast cancer after CDK4/6 inhibitors
Breast cancer (all types). Published April 2026. Reserves 'variant' for molecular alterations and separates subtype from pattern, updates the HER2 reporting categories so that no m...
Cervical cancer
Endometrial cancer with no specific molecular profile
Advanced or recurrent endometrial cancer
Biliary tract cancer (cholangiocarcinoma)
Non-small-cell lung cancer
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
San Francisco, CA
The funding rounds on company records, each with the source that states the figure.
$75m
$35m. Additional equity and venture debt closed 8 July 2026, bringing the Series C total to $150 million
$7.8bn. $115 per share in cash plus a $5 contingent value right; implied equity value $7.8 billion; completed 28 April 2026
$52m. Led by founding investor Mattias Westman; cumulative funding stated as over $185 million.
$300m. All-stock transaction valued at approximately 300 million US dollars; announced 2 March 2026, closed 4 May 2026
Hamilton Reserve Bank made an equity investment of undisclosed size and agreed to arrange a credit line of up to USD 20 million to support 2026 product sales
$1.0bn. USD 1 billion in cash, announced 8 June 2026; completion announced on the company website 29 July 2026
$100m. Oversubscribed; led by new investor Viking Global Investors
$48m. Announced via Business Wire, 6 May 2026, as listed on the company news page
$3.3bn. Upfront payment of $3.25 billion; up to $7.00 billion in total including clinical, regulatory and commercial milestones; announced 20 April 2026
Tranche B of EUR 6 million drawn from a European Investment Bank loan facility in April 2026
$35m. Credit facility from Trinity Capital replacing a prior Madryn Asset Management facility
$28m. Led by existing investors InnovaHealth Partners and Birchview Capital with new investors OSF Ventures and Colorado University Healthcare Innovation Fund; Madryn Asset Managem...
$1.1bn. USD 1.1 billion upfront plus up to USD 400 million in milestones; agreement announced 6 July 2026, completed 28 August 2026 per company website
$160m. CareDx agreed to pay $160 million cash up front plus up to $100 million in revenue milestones (announced 28 April 2026); completion announced July 2026.
$100m. Led by founding investor Deerfield Management; closed April 2026
$50m. USD 50 million financing from OrbiMed announced 20 April 2026; the company did not name the round, labelled Series B here for schema purposes only
Public follow-on private placement on Euronext Oslo: NOK 286 million gross, 65 million new shares at NOK 4.40
$350m. Oversubscribed private placement completed alongside the reverse merger with Galera Therapeutics; shares began trading on Nasdaq as OBX on 4 August 2026
Flexible bridge equity financing (warrants) with IRIS Capital Investment: up to 4 million new shares, gross proceeds up to about EUR 19.3 million over 24 months at the then share p...
Listed issuer financing exemption (LIFE) unit offering: approximately CAD 6.84 million closed 5 May 2026 with a final tranche to bring the total to CAD 7.52 million; led by Paradig...
CAD 6.04 million of 3.59 percent convertible debentures maturing April 2029, including CAD 2.76 million from CEO Adrian Mendes
PreciseOnco consortium (with Philips, IGEA, EIBIR and CIRSE) awarded EUR 14.9 million public funding from the EU Innovative Health Initiative plus EUR 9 million in-kind, EUR 23.9 m...
$70m. Brings total capital raised to over USD 240 million
Acquired by Cureety (Paris) in September 2026; financial terms not disclosed
All shares acquired by non-profit XenoTherapeutics for about 2.20 US dollars per share in cash plus a contingent value right; total deal value not stated
$125m. USD 125 million plus, led by Morgan Health; valuation stated as more than USD 2 billion
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
European Heart Journal
Lancet Oncology
JCO Precision Oncology
Gynecologic Oncology
JNCI Monographs
Journal of Cancer Research and Practice
International Journal of Gynecological Cancer
Israel Journal of Health Policy Research
Cell
Journal of Chromatography A
European Journal of Cancer
International Journal of Cancer
eBioMedicine
European Journal of Cancer
BMJ Oncology
Cancer Discovery
Cold Spring Harbor Perspectives in Biology
Gastroenterology
Dates a source states for something still to come: roadmap watch items, the readout calendar, company catalysts, and registry primary completion dates.
Expected date. Novartis announced the supplemental filing after the PSMAddition results in 2025. No action date has been disclosed; the year is our estimate.
Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Actual primary completion date on ClinicalTrials.gov.
Actual primary completion date on ClinicalTrials.gov.
Confirmed date. PDUFA target action date stated by Nuvalent when the FDA accepted the new drug application. Nuvalent's first potential approval.
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Confirmed date. Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee reviews GRAIL's premarket approval application.
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Confirmed date. Europe's largest oncology congress. Watch for: TROPION-Breast05, first-line ADC + IO data, late-breaking radioligand and bispecific ADC results.
Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Confirmed date. The breast cancer congress. Post-neoadjuvant TNBC ADC trials (ASCENT-05, TROPION-Breast03) and sac-TMT first-line TNBC data are candidates for presentation here or...
Confirmed date. Haematology's main congress: CAR-T, bispecifics, menin inhibitors, BCL-2 combinations.
Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...
Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...
Expected date. Topline positive 19 August 2026; hazard ratios and curves expected at a late-2026 congress (ESMO or SMR), with regulatory filings to follow.
Expected date. Full results presented at ASCO 2026 (primary stage III to IV endpoint not met; stage IV reduction reported).
Expected date. All-stock deal at $16.25 per share announced July 2026; the companies guided to a close in late 2026 or early 2027.
Expected date. Primary completion per registry falls in 2026; timing of topline is our estimate. Would complete the ADC + IO first-line picture alongside ASCENT-04.